Last reviewed · How we verify
mRNA-1403
mRNA-1403 is an mRNA-based vaccine designed to encode for the SARS-CoV-2 spike protein.
mRNA-1403 is an mRNA-based vaccine designed to encode for the SARS-CoV-2 spike protein. Used for COVID-19 prevention.
At a glance
| Generic name | mRNA-1403 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by instructing cells to produce the SARS-CoV-2 spike protein, which is then recognized by the immune system, eliciting a response against the virus. The goal is to provide immunity against COVID-19.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1403 CI brief — competitive landscape report
- mRNA-1403 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI